Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ann Mullally, M.D.

Co-Author

This page shows the publications co-authored by Ann Mullally and Benjamin Ebert.
Connection Strength

5.125
  1. Sinister symbiosis: pathological hematopoietic-stromal interactions in CML. Cell Stem Cell. 2013 Sep 05; 13(3):257-8.
    View in: PubMed
    Score: 0.585
  2. Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma. J Clin Oncol. 2012 Nov 20; 30(33):4168-70.
    View in: PubMed
    Score: 0.546
  3. Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am. 2012 Oct; 26(5):1065-81.
    View in: PubMed
    Score: 0.544
  4. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012 Jul 05; 120(1):166-72.
    View in: PubMed
    Score: 0.535
  5. STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation. Cancer Cell. 2010 Nov 16; 18(5):405-6.
    View in: PubMed
    Score: 0.482
  6. NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res. 2010 Aug 15; 16(16):4074-6.
    View in: PubMed
    Score: 0.469
  7. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010 Jun 15; 17(6):584-96.
    View in: PubMed
    Score: 0.468
  8. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436).
    View in: PubMed
    Score: 0.201
  9. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 09 12; 30(3):404-417.
    View in: PubMed
    Score: 0.180
  10. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015 Jan 08; 125(2):327-35.
    View in: PubMed
    Score: 0.158
  11. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014 Oct 13; 26(4):509-20.
    View in: PubMed
    Score: 0.157
  12. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014 Apr 07; 211(4):605-12.
    View in: PubMed
    Score: 0.152
  13. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood. 2013 May 02; 121(18):3692-702.
    View in: PubMed
    Score: 0.141
  14. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood. 2011 Oct 27; 118(17):4666-73.
    View in: PubMed
    Score: 0.127
  15. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011 Mar 03; 117(9):2567-76.
    View in: PubMed
    Score: 0.120
  16. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2018 Aug 02; 23(2):308-309.
    View in: PubMed
    Score: 0.051
  17. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2017 06 01; 20(6):785-800.e8.
    View in: PubMed
    Score: 0.047
  18. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One. 2014; 9(5):e96209.
    View in: PubMed
    Score: 0.038
  19. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 06; 489(7414):155-9.
    View in: PubMed
    Score: 0.034
  20. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia. 2013 Feb; 27(2):344-52.
    View in: PubMed
    Score: 0.034
  21. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7.
    View in: PubMed
    Score: 0.027
  22. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.